Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.
JAMA October 21, 2025 Reid Robison, Robert Barrow, Craig Conant et al. 22 citations
A single dose of MM120 (lysergide D-tartrate) reduces anxiety in a dose-dependent way in adults with moderate to severe generalized anxiety disorder. In a phase 2b randomized, double-blind, placebo-controlled trial with 198 participants, the 100-µg and 200-µg doses produced significantly greater reductions in Hamilton Anxiety Rating Scale scores at 4 weeks than placebo, with differences of -5.0 and -6.0 points, respectively. Lower doses (25 µg and 50 µg) did not differ from placebo. Common side effects included visual perceptual changes and nausea, which increased with dose.